Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Cholangiocarcinoma 10Acrocephalosyndactylia 6Carcinoma, Transitional Cell 5Neoplasm Metastasis 4Breast Neoplasms 4Gastrointestinal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Solid Tumor 2Recurrence 2Pancreatic Neoplasms 2Neoplasms 2Myeloproliferative Disorders 2Lung Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma 2Urinary Bladder Neoplasms 1Solid Tumor, Miscellaneous 1Sarcoma 1Oligodendroglioma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Unknown Primary 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Locally Advanced Unresectable Gastric Cancer 1Liposarcoma 1Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 14Injections 13Paclitaxel 10Nivolumab 10Docetaxel 9Cisplatin 9Capecitabine 9Bevacizumab 8toripalimab 7senaparib 7Fluorodeoxyglucose F18 7Cyclophosphamide 7tislelizumab 6atezolizumab 6Irinotecan 6Fluorouracil 6Gemcitabine 5fludarabine 4apatinib 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Carboplatin 4spartalizumab 3sintilimab 3pertuzumab 3olaparib 3camrelizumab 3Rifampin 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Solid Tumor × pemigatinib × Clear all
NCT06022289 2023-09-01

Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

Tianjin Medical University Second Hospital

Phase 2 Unknown
20 enrolled
Other solid neoplasm

Solid Tumor

NCT04258527 2021-07-23

Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
12 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡